

Limited Assurance for Calendar Year 2025 Scope 1, Scope 2, Scope 3 Categories 1-8 GHG Emissions

June 23, 2026

KERAMIDA Inc. (KERAMIDA) was engaged by ePharmIT to provide independent limited assurance greenhouse gas (GHG) verification of its calendar year 2025 Scope 1, Scope 2, and Scope 3 Categories 1-8 GHG emissions inventory. The data and calculations being verified cover the period from January 1, 2025, to December 31, 2025. The calculation of the GHG inventory is the sole responsibility of ePharmIT, in accordance with the GHG Protocol standards.

STATEMENT OF INDEPENDENCE

KERAMIDA affirms our independence from ePharmIT and is free from bias and conflicts of interest related to the assurance of the environmental data.

VERIFICATION ASSURANCE OPINION

Based on the process and procedures conducted, there is no evidence that the GHG emissions calculations and summary are not a fair representation of the actual GHG emissions data and information.

In KERAMIDA's opinion, ePharmIT has established an appropriate system for collecting, calculating, and analyzing quantitative data and information for the GHG emissions for the stated time period, scope, and level of assurance.

KERAMIDA'S APPROACH

Verification was conducted in accordance with ISO 14064-3: 2019 Specification with guidance for the validation and verification of GHG assertion. The scope of work was to provide limited assurance for the verification of ePharmIT's GHG emissions inventory.

Validation scope of the reporting company's GHG emissions

- Organizational boundaries: Operational Control Approach

Time Period

- January 1, 2025, to December 31, 2025

Level of Assurance

- Limited
- Materiality Threshold: 5% as suggested by ISO 14064-3 (2019)

KERAMIDA'S METHODOLOGY AND PROCEDURE

Procedure performed during the verification:

- Interviews with key personnel involved in the process of compiling, calculating, and preparing the emissions data report.
- Review of evidence and data in support of key disclosures in the emissions report.
- Review of a variety of data analytics to check the reasonableness of the data and calculations.
- A variety of re-calculation procedures to confirm stated quantities.
- Evaluation of the reasonableness of any assumptions used in support of disclosures.
- Review of how disclosures were presented and determine if they were representative of data and operations.

TABLE 1. CY2025 DATA VERIFIED BY KERAMIDA

Scope	CO ₂ e (MT)
Scope 1	1.15
Scope 2 (Location-Based)	0.46
Scope 2 (Market-Based)	0
Scope 3 Category 1	1,037.01
Scope 3 Category 2	100.13
Scope 3 Category 3 (Location-Based)	0.45
Scope 3 Category 4	Not Applicable
Scope 3 Category 5	Not Applicable
Scope 3 Category 6	Not Applicable
Scope 3 Category 7	Not Applicable
Scope 3 Category 8	Not Applicable

This verification statement, including the opinion expressed herein, is provided to ePharmIT and is solely for the benefit of ePharmIT in accordance with the terms of our agreement. We consent to the release of this statement by ePharmIT to other entities in order to provide disclosure, but without accepting or assuming any responsibility or liability on our part to any other party who may have access to this statement.

Signed by KERAMIDA Inc. on June 23, 2026:



Xuqing Xiong, P.E., M.S.
Accredited Lead GHG Verifier
Vice President, GHG & Sustainability Data
KERAMIDA Inc.
Indianapolis, Indiana, United States